News Focus
News Focus
Followers 58
Posts 7682
Boards Moderated 0
Alias Born 02/05/2016

Re: hope4patients post# 535434

Saturday, 11/19/2022 10:06:52 AM

Saturday, November 19, 2022 10:06:52 AM

Post# of 822238

What is your take on valuation if the company can scale to 12,000 patients per yr at Sawston after approval in the UK assuming a price per patient of about $210,000?



Two things.

First, throw that 12,000 number out if you're talking just MHRA approval. It doesn't matter if Sawston can make 12k per year because the UK doesn't have that many cases/year. You're looking at a quarter to a third of that number.

Second, we've heard multiple times from folks in the know that cost is an issue. $210,000/patient post approval isn't happening. I think their current actual price, were they approved, would be around $150,000. However, they have to get that down. I'm guessing $100,000-$120,000 is the target for now.

So at 4k patients/year and $100,000 per patient that $400M/year in the UK. Using your multiple of 15 that is an MHRA approval value of around $6B which I think is spot on for a starting point. You will of course have to adjust for high likelihood of FDA approval and Direct value, so I think you're looking at a short term price target of around $8-10B immediately after MHRA approval.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News